Laville Solène M, Vendar Janice, Massy Ziad A, Gras-Champel Valérie, Moragny Julien, Frimat Luc, Laville Maurice, Jacquelinet Christian, Pecoits-Filho Roberto, Alencar De Pinho Natalia, Hamroun Aghilès, Liabeuf Sophie
Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, Amiens, France.
MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.
Clin Kidney J. 2024 Nov 18;18(1):sfae357. doi: 10.1093/ckj/sfae357. eCollection 2025 Jan.
We sought to comprehensively describe drug-related components associated with acute kidney injury (AKI) in patients with chronic kidney disease (CKD), describing the incidence of drug-related AKI, the proportion of preventable AKI, identified the various drugs potentially associated with it, explored the risk factors, and assessed the 1-year incidences of the recurrence of drug-related AKI, kidney failure, and death.
CKD-REIN is a French national prospective cohort of 3033 nephrology outpatients with a confirmed diagnosis of CKD (eGFR <60 ml/min/1.73 m²). AKIs and adverse drug reactions (ADRs) were prospectively identified from hospital reports, medical records, and patient interviews. Expert nephrologists used the KDIGO criteria to adjudicate all stages of AKI, and expert pharmacologists used validated tools to adjudicate ADRs (including drug-related AKIs).
Over a median [interquartile range] period of 4.9 [3.4-5.1] years, 832 cases of AKI were reported in 639 (21%) of the 3033 study participants. The drug-related component associated with AKI accounted for 236 cases, and 28% were judged to be preventable or potentially preventable. The three most frequently implicated drug classes were diuretics, renin-angiotensin system inhibitors, and contrast agents. A history of cardiovascular events, diabetes, lower levels of hemoglobin and eGFR, poor medication adherence, and ≥5 drugs taken daily were associated with a greater risk of drug-related AKI. Full recovery was not attained in 64 (27%) of the 236 cases of drug-related AKI. The 1-year cumulative incidences of recurrence of drug-related AKI, kidney replacement therapy, and death were 7%, 15%, and 11%, respectively, after the first drug-related AKI.
Drug-related AKI is prevalent among patients with CKD. Even though a substantial proportion of these events were classified as stage 1, our findings point to a poor prognosis.
我们试图全面描述慢性肾脏病(CKD)患者中与急性肾损伤(AKI)相关的药物因素,描述药物相关性AKI的发生率、可预防AKI的比例,确定与之潜在相关的各类药物,探究危险因素,并评估药物相关性AKI复发、肾衰竭及死亡的1年发生率。
CKD-REIN是一项法国全国性前瞻性队列研究,纳入3033例确诊为CKD(估算肾小球滤过率[eGFR]<60 ml/min/1.73 m²)的肾脏病门诊患者。通过医院报告、病历及患者访谈前瞻性识别AKI和药物不良反应(ADR)。肾脏病专家使用KDIGO标准判定AKI的所有阶段,药理专家使用经过验证的工具判定ADR(包括药物相关性AKI)。
在中位[四分位间距]4.9[3.4 - 5.1]年的观察期内,3033例研究参与者中有639例(21%)报告了832例AKI。与AKI相关的药物因素导致236例发病,其中28%被判定为可预防或潜在可预防。最常涉及的三类药物为利尿剂、肾素 - 血管紧张素系统抑制剂及造影剂。心血管事件病史、糖尿病、血红蛋白及eGFR水平较低、用药依从性差以及每日服用≥5种药物与药物相关性AKI的发生风险较高相关。236例药物相关性AKI病例中,64例(27%)未完全恢复。首次发生药物相关性AKI后,药物相关性AKI复发、肾脏替代治疗及死亡的1年累积发生率分别为7%、15%和11%。
药物相关性AKI在CKD患者中普遍存在。尽管这些事件中很大一部分被归类为1期,但我们的研究结果表明预后较差。